Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study.
Ute BlassmannAnka C RoehrOtto R FreyCornelia Vetter-KerkhoffNiklas ThonWilliam HopeJosef BriegelVolker HugePublished in: Critical care (London, England) (2016)
Administration of higher-than-standard doses of meropenem and therapeutic drug monitoring in both serum and CSF should be considered to individualise meropenem dosing in neurocritical care patients with ventriculitis.